Loading clinical trials...
Loading clinical trials...
Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is sponsoring this trial.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Bakersfield, California, United States
La Jolla, California, United States
San Diego, California, United States
Savannah, Georgia, United States
South Bend, Indiana, United States
Baltimore, Maryland, United States
Albuquerque, New Mexico, United States
Winston-Salem, North Carolina, United States
Start Date
August 24, 2006
Primary Completion Date
July 8, 2008
Completion Date
March 25, 2009
Last Updated
April 8, 2021
45
ACTUAL participants
Sagopilone (ZK 219477) + carboplatin
DRUG
Lead Sponsor
Bayer
NCT07213804
NCT06051695
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions